Share this article on:

Abstract Index

JAIDS Journal of Acquired Immune Deficiency Syndromes: April 2013 - Volume 62 - Issue - p 26–30
doi: 10.1097/01.qai.0000429232.99877.23
Abstract Index

A101—Pattern of Mycobacterial Infections and their Associations with HIV among Laboratory Confirmed Cases of Pulmonary Tuberculosis in Nigeria

Gumel Aliyu, Institute of Human Virology Nigeria

A102—New Prevention Technologies, what does it mean for Nigeria?

John Idoko, National Agency for Control of AIDS

A103—Challenges of staying on the course for a HIV vaccine to end the epidemic in Africa

Chidi Nweneka, African AIDS Vaccine Partnership

A104—Improving laboratory capacity in Africa through step-wise accreditation program

Alash’le Abimiku, Institute of Human Virology

A105—Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda

Andrew Kambugu, Makerere University College of Health Sciences

A106—Neurocognitive Impairment among Treatment-Naïve HIV-Infected Individuals in Nigeria

Walter Royal III, University of Maryland School of Medicine

A107—Lymphoma incidence and HIV-related lymphoma subtypes seen at Tygerberg Academic Hospital, Western Cape, South Africa, 2002-2011

Emmanuel A. Abayomi, Tygerberg Hospital, Stellenbosch University

B101—Ten Draconian Changes in HIV Care for 2013

John Bartlett, Johns Hopkins University School of Medicine

B102—AIDSRelief: Lessons Learned

Bruce Gilliam, Institute of Human Virology

B103—The Zambian Medical Education Program

Lottie Hachaambwa, Maryland Global Initiatives Corporation (MGIC) Zambia

B104—Integrated Prevention of HIV: The Way Forward

Myron Cohen, University of North Carolina

B105—RV144: Progress in correlates, breakthrough viruses, and clinical development

Jerome Kim, US Military HIV Research Program

B106—New Nucleotides for the treatment of HIV infection

James Rooney, Gilead Sciences

B107—Results of a phase 1 using CCR5 Deficiency with Zinc Finger Nuclease-modified Autologous CD4 T Cells (SB-728-T) in HIV-infected Subjects

Pablo Tebas, University of Pennsylvania

B108—Therapeutic DNA vaccination in HIV-infected children and adolescents: 96 weeks data from the PEDVAC Trial

Paolo Rossi, Children Hospital “Bambino Gesu”

B109—Vacc-4x and Vacc-C5: Two peptide-based therapeutic HIV vaccine candidates

Maja Sommerfelt, Bionor Immuno

B110—Treatment for HCV in HIV Coinfected subjects: A new era of hope?

Anuoluwapo Osinusi, CRMP, SAIC-Frederick Inc/NIAID, NIH

B111—Genotypic resistance patterns in patients failing first line art regimen in Zambia

Ignace Gashongore, Institute of Human Virology, Zambia

B112—An Evaluation of Distance and its Impact on Long-term Follow up Outcomes in a Rural HIV Clinic in Northern Haiti

Nephthalie Mesidor, Institute of Human Virology Haiti

B113—Why Are They Dying? Describing Factors Associated With Mortality Among ART Patients in Rural Haiti

Barbara Bastien, Institute of Human Virology Haiti

B114—Proficiency Testing As a Quality Assessment Methodology in Acid Fast Bacilli Microscopy: The Experience of AIDSRelief

Michael Mukiibi, Institute of Human Virology Nigeria

B115—Effects of a Maternal Infant HIV Care Clinic for HIV-infected mothers and exposed infants on follow up postnatal HIV testing and care in Southeastern Nigeria: A retrospective review

Anthea Nwandu, Institute of Human Virology Nigeria

B116—Implementation of Cervical cancer screening services at 9 IHV/PEPFAR supported ART clinics in Uganda; Successes and challenges

Emmanuel Mugisa, Institute of Human Virology Uganda

C101—Viral Reservoirs in Elite Suppressors; a Possible Model for a Functional Cure?

Joel Blankson, Johns Hopkins University

C102—Cell-intrinsic HIV-1 immune defense in elite controllers

Mathias Lichterfeld, Massachusetts General Hospital

C103—Identification, purification and characterization of latently-infected cells using novel fluorescent HIV viruses

Eric Verdin, University of California Francisco

C104—Flow virometry: A nanotechnology for analysis of individual viral particles

Leonid Margolis, National Institutes of Health

C105—Glycosylation in HIV Transmission

Jim Arthos, National Institutes of Health

C106—Distinguishing Features of Transmitted/Founder HIV-1

George Shaw, University of Pennsylvania

C107—Preservation of Th17 cells and reduced microbial translocation in SIV-infected rhesus macaques treated with IL-21

Mirko Paiardini, Emory

C108—Impact of a live attenuated SIV vaccine on early events in transmission

Ashley Haase, University of Minnesota

D101—The cardinal rule of antibody - and CTL-eliciting vaccine design: specificity in a biological context

Ellis Reinherz, Dana Farber Harvard

D102—Molecular structures of trimeric HIV-1 and SIV envelope glycoproteins

Sriram Subramaniam, National Institutes of Health

D103—Structure, dynamics and antigenicity in HIV Env: A bridge from structure to phenotype and function

Kelly Lee, University of Washington

D104—Structural definition of new transitional epitopes exposed by CD4 binding to the HIV-1

Marzena Pazgier, Institute of Human Virology

D105—Reverse engineering HIV vaccines

William Schief, IAVI and The Scripps Research Institute

D106—Overcoming HIV Pathways for Escape using Rationally-Designed Anti-HIV Antibodies

Pamela Bjorkman, California Institute of Technology

D107—Effective CD4-binding-site antibodies: Atomic-level structures and ontogenies

Peter Kwong, National Institute of Allergy and Infectious Diseases

D108—Synthetic HIV-1 Glycopeptides Enable Characterization of Fine Epitopes of Broadly Neutralizing Antibody PG9

Lai-Xi Wang, Institute of Human Virology

D109—The role of Siglec in HIV infection

Peter Sun, National Institutes of Health

E101—Advances in Preventive HIV Vaccine Development

Nelson Michael, U.S. Military HIV Research Program

E102—Magnitude, Breadth and Duration of HIV-1 Vaccine-Elicited Neutralizing Antibody Responses

David Montefiori, Duke University Medical Center

E103—HIV-1 Vaccine Elicited IgA and IgG Antibody Specificities

Georgia Tomaras, Duke University Medical Center

E104—Identification of Three Distinct Epitope Regions in the V2 Portion of gp120

Susan Zolla-Pazner, New York University

E105—Exploring the role of conformational heterogeneity in the V1/V2 domain of HIV-1 gp120 on the immunological properties of Env immunogens

Abraham Pinter, New Jersey Medical School

E106—Diversity of Antibody Germline Gene and HIV-1 Infection: Implication for HIV-1 Vaccine

Yongjun Guan, Institute of Human Virology

E107—Complexity of human naïve B cell repertoires: The starting point for induction of neutralizing antibodies

James Crowe, Vanderbilt

E108—Analysis of Broad Neutralizing B Cell Lineages to Guide HIV-1 Immunogen Design

Barton Haynes, Duke University

E109—Ending the HIV/AIDS Pandemic: Research and Implementation

Anthony Fauci, National Institutes of Health

E110—Antibodies to the gp120 envelope protein in protection of macaques from SIVmac251 acquisition

Genoveffa Franchini, National Institutes of Health

E111—Vaccine-microbicide combination studies in a rhesus macaque vaginal transmission model

John Moore, Weill Medical College of Cornell University

E112—DNA and combination vaccines for a durable and effective response

George Pavlakis, National Cancer Institute

E113—SIV control by vaccine-based Gag/Vif-specific CTL induction

Tetsuro Matano, The University of Tokyo

E114—Rational Design and Clinical Development of New Adjuvants

Steven Reed, Infectious Disease Research

G101—Studies at the oncogenic virus/host interface: Dynamic regulation of Epstein-Barr virus-mediated B cell immortalization

Micah Luftig, Duke University

G102—Activation of differentiation-dependent human papillomavirus life cycle through the ATM DNA damage pathway

Lou Laimins, Northwestern University

G103—The mechanisms by which HPV vaccines induce protection against HPV-associated cancers

Doug Lowy, National Institutes of Health

G104—Molecular Signatures in Human Liver Cancer

Franco Buonaguro, Istituto Nazionale Tumori “Fond. G. Pascale”

G105—Profibrogenic Chemokines and Viral Evolution Predict Rapid Progression of Hepatitis C to Cirrhosis

Patrizia Farci, National Institutes of Health

G106—Pathogenic roles of HTLV-1 bZIP factor gene

Masao Matsuoka, Institute for Virus Research, Kyoto University

G107—HIV-1 p17 variants induces Akt phosphorylation and B cell growth

Arnaldo Caruso, University of Brescia

© 2013 Lippincott Williams & Wilkins, Inc.